|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: APOH |
Gene summary for APOH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | APOH | Gene ID | 350 |
| Gene name | apolipoprotein H | |
| Gene Alias | B2G1 | |
| Cytomap | 17q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P02749 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 350 | APOH | NAFLD1 | Human | Liver | NAFLD | 2.56e-03 | 3.97e-01 | -0.04 |
| 350 | APOH | S43 | Human | Liver | Cirrhotic | 3.30e-12 | -2.95e-01 | -0.0187 |
| 350 | APOH | HCC1_Meng | Human | Liver | HCC | 2.06e-40 | 7.00e-01 | 0.0246 |
| 350 | APOH | HCC2_Meng | Human | Liver | HCC | 2.08e-35 | -8.81e-01 | 0.0107 |
| 350 | APOH | cirrhotic1 | Human | Liver | Cirrhotic | 1.62e-11 | -6.12e-02 | 0.0202 |
| 350 | APOH | cirrhotic2 | Human | Liver | Cirrhotic | 2.48e-11 | -8.06e-02 | 0.0201 |
| 350 | APOH | cirrhotic3 | Human | Liver | Cirrhotic | 3.78e-05 | -3.36e-01 | 0.0215 |
| 350 | APOH | HCC1 | Human | Liver | HCC | 6.73e-36 | 7.65e+00 | 0.5336 |
| 350 | APOH | HCC2 | Human | Liver | HCC | 4.57e-44 | 7.09e+00 | 0.5341 |
| 350 | APOH | HCC5 | Human | Liver | HCC | 1.00e-03 | 3.14e+00 | 0.4932 |
| 350 | APOH | Pt13.a | Human | Liver | HCC | 4.06e-79 | 1.12e+00 | 0.021 |
| 350 | APOH | Pt13.b | Human | Liver | HCC | 2.37e-66 | 8.62e-01 | 0.0251 |
| 350 | APOH | Pt13.c | Human | Liver | HCC | 7.64e-31 | 9.89e-01 | 0.0076 |
| 350 | APOH | Pt14.a | Human | Liver | HCC | 5.14e-08 | 5.40e-01 | 0.0169 |
| 350 | APOH | Pt14.b | Human | Liver | HCC | 1.63e-15 | 8.34e-01 | 0.018 |
| 350 | APOH | Pt14.d | Human | Liver | HCC | 1.78e-14 | 5.54e-01 | 0.0143 |
| 350 | APOH | S014 | Human | Liver | HCC | 2.22e-26 | 2.62e+00 | 0.2254 |
| 350 | APOH | S015 | Human | Liver | HCC | 2.10e-18 | 2.94e+00 | 0.2375 |
| 350 | APOH | S016 | Human | Liver | HCC | 2.43e-31 | 2.56e+00 | 0.2243 |
| 350 | APOH | S027 | Human | Liver | HCC | 3.87e-05 | 1.08e+00 | 0.2446 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066382 | Liver | NAFLD | neutral lipid metabolic process | 32/1882 | 129/18723 | 1.06e-06 | 5.35e-05 | 32 |
| GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
| GO:1903035 | Liver | NAFLD | negative regulation of response to wounding | 26/1882 | 94/18723 | 1.18e-06 | 5.66e-05 | 26 |
| GO:0072376 | Liver | NAFLD | protein activation cascade | 8/1882 | 12/18723 | 3.51e-06 | 1.40e-04 | 8 |
| GO:19030366 | Liver | NAFLD | positive regulation of response to wounding | 21/1882 | 72/18723 | 4.93e-06 | 1.83e-04 | 21 |
| GO:0051918 | Liver | NAFLD | negative regulation of fibrinolysis | 7/1882 | 10/18723 | 9.36e-06 | 3.02e-04 | 7 |
| GO:0072378 | Liver | NAFLD | blood coagulation, fibrin clot formation | 7/1882 | 10/18723 | 9.36e-06 | 3.02e-04 | 7 |
| GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
| GO:0030194 | Liver | NAFLD | positive regulation of blood coagulation | 10/1882 | 23/18723 | 3.44e-05 | 8.81e-04 | 10 |
| GO:1900048 | Liver | NAFLD | positive regulation of hemostasis | 10/1882 | 23/18723 | 3.44e-05 | 8.81e-04 | 10 |
| GO:0050820 | Liver | NAFLD | positive regulation of coagulation | 10/1882 | 24/18723 | 5.36e-05 | 1.22e-03 | 10 |
| GO:0031638 | Liver | NAFLD | zymogen activation | 16/1882 | 60/18723 | 2.08e-04 | 3.60e-03 | 16 |
| GO:00508787 | Liver | NAFLD | regulation of body fluid levels | 60/1882 | 379/18723 | 2.61e-04 | 4.23e-03 | 60 |
| GO:00510043 | Liver | NAFLD | regulation of lipoprotein lipase activity | 7/1882 | 20/18723 | 2.44e-03 | 2.27e-02 | 7 |
| GO:0032102 | Liver | NAFLD | negative regulation of response to external stimulus | 60/1882 | 420/18723 | 3.34e-03 | 2.93e-02 | 60 |
| GO:00016676 | Liver | NAFLD | ameboidal-type cell migration | 65/1882 | 475/18723 | 6.32e-03 | 4.69e-02 | 65 |
| GO:00516046 | Liver | Cirrhotic | protein maturation | 121/4634 | 294/18723 | 3.54e-10 | 1.68e-08 | 121 |
| GO:004206012 | Liver | Cirrhotic | wound healing | 155/4634 | 422/18723 | 2.12e-08 | 7.56e-07 | 155 |
| GO:190303611 | Liver | Cirrhotic | positive regulation of response to wounding | 38/4634 | 72/18723 | 2.98e-07 | 7.18e-06 | 38 |
| GO:009030311 | Liver | Cirrhotic | positive regulation of wound healing | 33/4634 | 59/18723 | 3.00e-07 | 7.21e-06 | 33 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa049796 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
| hsa0497911 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
| hsa049792 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
| hsa049793 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
| hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| APOH | SNV | Missense_Mutation | c.951T>A | p.Asp317Glu | p.D317E | P02749 | protein_coding | deleterious(0) | possibly_damaging(0.493) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| APOH | SNV | Missense_Mutation | c.595N>C | p.Glu199Gln | p.E199Q | P02749 | protein_coding | deleterious(0.02) | benign(0.293) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| APOH | deletion | Frame_Shift_Del | novel | c.1028delA | p.Lys343SerfsTer24 | p.K343Sfs*24 | P02749 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| APOH | SNV | Missense_Mutation | c.455C>T | p.Thr152Ile | p.T152I | P02749 | protein_coding | tolerated(0.2) | benign(0.006) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| APOH | SNV | Missense_Mutation | novel | c.739N>C | p.Glu247Gln | p.E247Q | P02749 | protein_coding | tolerated(0.13) | benign(0.388) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| APOH | SNV | Missense_Mutation | rs765836638 | c.920N>A | p.Cys307Tyr | p.C307Y | P02749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A3EO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| APOH | SNV | Missense_Mutation | rs35449692 | c.961N>A | p.Glu321Lys | p.E321K | P02749 | protein_coding | tolerated(0.14) | benign(0.029) | TCGA-JX-A3PZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| APOH | SNV | Missense_Mutation | c.885N>T | p.Lys295Asn | p.K295N | P02749 | protein_coding | tolerated(0.19) | benign(0.169) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| APOH | SNV | Missense_Mutation | rs763687723 | c.395C>T | p.Pro132Leu | p.P132L | P02749 | protein_coding | tolerated(0.34) | benign(0.125) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| APOH | SNV | Missense_Mutation | rs35449692 | c.961N>A | p.Glu321Lys | p.E321K | P02749 | protein_coding | tolerated(0.14) | benign(0.029) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |